Cancer and venous thromboembolism

Area of Science:

• Oncology
• Hematology
• Vascular Medicine

Background:

• Neoplastic cells can directly or indirectly activate the coagulation cascade, leading to increased thrombin generation.
• Cancer and chemotherapy can impair endothelial cell function and down-regulate natural anticoagulant mechanisms, promoting hypercoagulability.
• Platelet function defects can further disrupt normal hemostasis in cancer patients.

Purpose of the Study:

• To review the mechanisms of hypercoagulability in cancer patients.
• To outline current recommendations for primary and secondary prevention of venous thrombosis in this population.
• To discuss the diagnostic implications of venous thrombosis in uncovering occult malignancies.

Main Methods:

• Literature review of studies on cancer-associated thrombosis.
• Analysis of mechanisms linking cancer, coagulation, and endothelial dysfunction.
• Synthesis of clinical guidelines for thrombosis prevention and management in cancer.

Main Results:

• Primary prevention of venous thrombosis is recommended for cancer patients undergoing chemotherapy, with central venous catheters, or hospitalized for immobilization/surgery.
• Secondary prevention typically requires anticoagulation, with warfarin resistance necessitating adjusted high-dose heparin or inferior vena cava filters for bleeding complications.
• Diagnosing venous thrombosis can prompt investigation for occult cancer, though extensive screening is not cost-effective.

Conclusions:

• Cancer patients are at high risk for venous thromboembolism due to complex prothrombotic mechanisms.
• Risk stratification and tailored prevention strategies are essential for managing cancer-associated thrombosis.
• Venous thrombosis can serve as an indicator for underlying malignancy, guiding diagnostic workup.